Friday , 14 December 2018

Lumoxiti: Treatment for refractory hairy cell leukemia (HCL)

Lumoxiti injection is a new medicine for intravenous use for the treatment of adult patients with refractory hairy cell leukemia (HCL) who have received minimum two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and very first drug of this type of treatment for patients with HCL. It is rare and slow growing cancer of the blood in which the bone marrow makes too many B Cells, a type of white blood cells that fights infection. For more details click here.

Scroll To Top